Friday, June 19, 2026 · Covering: Mon–Fri this week
TL;DR
Olin and Huntsman announced a $12B+ all-stock merger on Monday to create a North American chemicals giant — the biggest industrials deal of the week. Yum! Brands simultaneously announced it's selling Pizza Hut for $2.7B as it sheds its last owned brand to go fully asset-light. The macro backdrop got more complicated: new Fed Chair Kevin Warsh held rates steady at his first FOMC meeting but the dot plot flipped hawkish, with the median official now expecting a rate hike later this year — rattling markets before a partial recovery.
TOP 3 DEALS
DEAL 01
Industrials / Chemicals
TRANSACTION VALUE~$12B+ combined enterprise value (all-stock)
STRUCTUREMerger of Equals; Huntsman holders get 0.5476 Olin shares per share
OLIN ADVISORSLazard (financial); Cravath, Swaine & Moore + Sidley Austin (legal)
HUNTSMAN ADVISORSCiti + Morgan Stanley (financial); Kirkland & Ellis (legal)
ANNOUNCEDJune 16, 2026
EXPECTED CLOSEH1 2027 (subject to shareholder + regulatory approval)
Olin (a chlorine and ammunition chemicals producer) and Huntsman (a specialty chemicals company) are combining in a no-premium, all-stock "merger of equals" — meaning neither side is paying a takeover premium; shareholders on both sides simply swap into the new combined entity based on an agreed exchange ratio. The combined company, to be called OlinHuntsman and headquartered in Texas, will have a combined enterprise value exceeding $12B and aims to cut costs by integrating their overlapping chemical supply chains. PR Newswire ↗
Why it matters for recruiting: This is a textbook Merger of Equals — a structure you'll absolutely get asked about. Key talking points: (1) no control premium paid, so the deal is justified purely on synergies; (2) the exchange ratio is the central negotiating lever; (3) the ownership split (~54.5% Olin / ~45.5% Huntsman) determines who effectively controls the combined board. Be ready to explain why companies choose all-stock vs. cash and how an MOE differs from a standard acquisition.
DEAL 02
Consumer / Restaurant
TRANSACTION VALUE$2.7B aggregate
BUYERSLongRange Capital (PE) — international ops; Yum China — China ops
SELLER ADVISORS (YUM!)Goldman Sachs + Barclays (financial); Weil, Gotshal & Mayer Brown (legal)
BUYER ADVISORSTBD
ANNOUNCEDJune 16, 2026
EXPECTED CLOSEQ3 2026
Yum! Brands — parent of KFC, Taco Bell, and Pizza Hut — is selling Pizza Hut in a split transaction: LongRange Capital (PE) buys the international franchise business, while Yum China buys the China operations. This leaves Yum! with only KFC and Taco Bell, completing a long-running strategy to become a pure-play franchise operator that collects royalties rather than running restaurants directly. Yum! also announced a $4B stock buyback alongside the sale. Business Wire ↗
Why it matters for recruiting: Classic strategic divestiture driven by the "asset-light" thesis — Yum! wants to own zero restaurants and collect only franchise royalty fees, which are more predictable and require far less capital. Frame this in an interview as portfolio rationalization: shedding an underperforming brand to simplify the business and return capital to shareholders. Also note: splitting one asset across two buyers (geographic carve-out) is common when a target has complex multi-regional operations.
DEAL 03
Healthcare / Biopharma
TRANSACTION VALUE$10.6B equity value ($9.4B net of cash); $124/share
PREMIUM40% to last close; 26% to 30-day VWAP
GSK ADVISORSLeerink Partners + Citi (financial); Davis Polk + Slaughter and May (legal)
NUVALENT ADVISORSCenterview Partners + Jefferies (financial); Ropes & Gray (legal)
ANNOUNCEDJune 9, 2026
STRUCTUREAll-cash tender offer
UK pharma giant GSK is buying Nuvalent, a Cambridge-based biotech with a pipeline focused on next-generation ROS1 and ALK inhibitors — targeted therapies for non-small cell lung cancer. GSK is paying $124/share in cash via a tender offer (going directly to shareholders, bypassing a full shareholder vote), representing a 40% premium to Nuvalent's pre-announcement price. The deal gives GSK a potential blockbuster oncology asset as it faces patent expirations on existing drugs over the next several years. CNBC ↗
Why it matters for recruiting: Pharma M&A is almost entirely driven by pipeline acquisition — large pharma companies buy clinical-stage biotechs to replace revenue as their own drugs lose patent protection (the "patent cliff"). Know the distinction between a tender offer (acquirer goes directly to shareholders with a cash bid) vs. a traditional merger (requires target shareholder vote). Also note the advisor lineup: Centerview (elite sell-side M&A boutique) and Leerink (healthcare-specialist boutique on buy-side) — knowing boutique specializations by sector signals sophistication in interviews.
SECTOR SIGNAL
DEFENSE / AEROSPACE
Defense startup VC funding hit an all-time record in 2026, surpassing $14.6B — up 52% from $9.6B in 2025 — as the Pentagon actively courts venture capital for drones, AI, and munitions. Anduril leads at a $30.5B valuation. Crunchbase ↗ Redwire also secured a multi-year NATO Penguin Mk3 UAS contract and a $15M Army Stalker drone follow-on order this week. StocksToTrade ↗
TECH / TMT
AI infrastructure M&A continues at mega-scale: a consortium of BlackRock, Microsoft, Nvidia, MGX, and Elon Musk's xAI agreed to acquire Aligned Data Centers in a ~$40B deal, reflecting hyperscaler competition to lock up power and compute capacity for AI workloads. Techoble ↗
INDUSTRIALS
Beyond the Olin/Huntsman MOE, the broader theme in industrial chemicals is consolidation under pricing pressure and overcapacity. Commodity chemical producers unable to pay acquisition premiums are turning to all-stock mergers of equals to achieve scale — expect more of this structure in cyclical industrials. PlasticsToday ↗
HEALTHCARE / OTHER
GSK's $10.6B Nuvalent deal (Deal 03) is part of a broader wave of Big Pharma M&A driven by patent cliff anxiety. GSK, Pfizer, and AstraZeneca are all competing to acquire oncology pipelines before blockbuster revenue rolls off patent protection in the next 3–5 years. PharmTech ↗
M&A / LEVERAGED FINANCE
The $55B Electronic Arts leveraged buyout — the largest LBO in history, backed by Saudi Arabia's PIF, Silver Lake, and Affinity Partners — is expected to close by June 30. Meanwhile, the Fed's hawkish tilt this week (dot plot flipping to a potential hike) matters directly for leveraged finance: LBO economics depend heavily on debt financing rates. Any upward move in the risk-free rate increases the cost of the high-yield bonds and leveraged loans that fund sponsor deals, compressing equity returns. High yield spreads remain contained (~278bps OAS), but a hike could slow new issuance fast. Intellizence ↗
MARKET TONE
Fed holds, but dot plot goes hawkish. Kevin Warsh chaired his first FOMC meeting and held rates at 3.50–3.75% — but the median policymaker now projects a rate hike by year-end, a reversal from March's implied cut. The Fed raised its 2026 PCE inflation forecast from 2.7% to 3.6%. Futures markets are pricing in zero cuts for the rest of 2026. Fox Business ↗
Markets whipsawed then bounced. S&P 500 fell ~1.2% and Nasdaq ~1.3% on June 17 after the hawkish dot plot. Both rebounded sharply on June 18: S&P +1.9% (to 7,573) and Nasdaq +3.0% (to 26,667), partly aided by news the U.S. ended an Iran blockade. TheStreet ↗
10-Year Treasury at 4.46%. Yields ticked up ~3.5bps post-FOMC, reflecting higher-for-longer expectations. Rising long-term rates compress DCF valuations — a higher discount rate lowers the present value of future cash flows, making it harder to justify M&A deal prices at current levels. StockTitan ↗
Warsh signals structural Fed overhaul. Alongside the rate decision, Warsh unveiled internal task forces to overhaul major Federal Reserve operations — signaling a more hawkish and less interventionist central bank going forward, a sharp contrast from the Powell era's dovish tilt. CNBC ↗
Credit markets stable despite rate anxiety. Investment-grade OAS ~80bps; HY spreads ~278bps — tight by historical standards, suggesting credit hasn't yet repriced for a hike. But if the Fed follows through, leveraged loan and HY bond issuance volumes could pull back sharply as deal economics get squeezed. Trading Economics ↗
INTERVIEW ANGLE
TOPIC: MERGER OF EQUALS — WHAT IT IS AND WHY IT MATTERS
The Olin/Huntsman deal is a rare, textbook Merger of Equals (MOE) — worth knowing cold for any M&A interview. In a standard acquisition, a buyer pays a premium above the target's stock price to win shareholder approval. In an MOE, there's no meaningful premium; instead, both companies agree that combining at roughly equal valuations creates more value than either can alone. The deal is structured as an all-stock exchange using a fixed ratio.
Exchange ratio: Huntsman shareholders receive 0.5476 Olin shares per Huntsman share. This ratio is set at announcement and reflects each company's relative negotiated value. If Olin's stock moves before closing, Huntsman holders still get the same number of shares — both sides bear market risk until close (unlike a fixed-price cash deal).
No premium = pure synergy bet. Because no control premium is paid, the deal's entire value case rests on cost synergies (overlapping supply chains, procurement, headcount). If synergies don't materialize, neither company's shareholders got a premium as compensation — that's the risk.
Ownership split matters. Olin ~54.5% / Huntsman ~45.5%. Despite being called equals, Olin effectively controls OlinHuntsman — a common tension in these structures that plays out in board composition negotiations.
Why all-stock? Neither side wants to take on debt or pay a premium in cash. All-stock also means both sets of shareholders stay invested in the combined upside — it signals conviction from both boards.
How to bring it up: If asked "what deals are you following?" lead with Olin/Huntsman and say: "It's a rare Merger of Equals in industrials — I've been thinking about how the absence of a control premium shifts the entire value creation burden onto synergy realization, and how that changes the negotiation dynamic versus a traditional acquisition." That framing signals you understand deal mechanics beyond just reading the headline number.